1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIA Small Business Innovation Research (SBIR) Program Phase I is sponsored by National Institute on Aging (NIA). This program invites applications to NIA's SBIR program to encourage research on, and the commercialization of, novel therapies, devices, products, and healthcare programs and practices to prevent the onset of Alzheimer's Disease (AD) and AD-related dementias (ADRD), and to redu…
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: United States small business concerns (SBCs). Confirm the full requirements in the official notice before applying.
The current listing shows up to $700,000 for Phase I AD/ADRD projects; up to $500,000 for other Phase I projects within NIA mission. Up to $3 Million for Phase II AD/ADRD projects; up to $2.5 Million for other Phase II projects within NIA mission. Verify award ceilings, matching requirements, and allowable costs in the official notice.
NIA Small Business Innovation Research (SBIR) Program Phase I is funded by National Institute on Aging (NIA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The National Institute on Aging's FY 2026 AD/ADRD portfolio consolidates the dementia research infrastructure layer — NCRAD, NACC, the new AI and Technology Collaboratory Coordinating Center — into a small number of large, often single-source cooperative agreements. The $113M new-research increment goes elsewhere. For investigators submitting in FY 2026, the structural change matters more than the headline dollar number.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article